Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Dr Mulvey on Real-World Treatment Discontinuation Data for First-Line BTK Inhibitors in CLL
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Dr Cohen on Phase 1 Efficacy Data for Cevostamab in R/R Myeloma
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5